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Allogeneic bone marrow and peripheral blood stem cell transplantations are curative treatment modalities
for adult T cell leukemia/lymphoma (ATLL) because of the intrinsic graft-versus-ATLL effect. However, limited
information is available regarding whether cord blood transplantation (CBT) induces a curative graft-versus-
ATLL effect against aggressive ATLL. To evaluate the effect of CBT against ATLL, we retrospectively analyzed
data from 175 patients with ATLL who initially underwent single-unit CBT. The 2-year overall survival (OS)
rate was 20.6% (95% conﬁdence interval [CI], 13.8% to 27.4%). A multivariate analysis revealed that the
development of graft-versus-host disease (GVHD) was a favorable prognostic factor for OS (hazard ratio, .10;
95% CI, .01 to .94; P ¼ .044). Furthermore, the 2-year OS (42.7%; 95% CI, 28.1% to 56.6%) of patients with grade
1 to 2 acute GVHD was higher than that of patients without acute GVHD (24.2%; 95% CI, 11.2% to 39.8%;
P ¼ .048). However, the cumulative incidence of treatment-related mortality (TRM) was high (46.1%; 95% CI,
38.2% to 53.7%), and early death was particularly problematic. In conclusion, CBT cures patients with ATLL
partly through a graft-versus-ATLL effect. However, novel interventions will be required, particularly in the
early phase, to reduce TRM and optimize GVHD.
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Adult T cell leukemia/lymphoma (ATLL), an aggressive
peripheral T cell neoplasm caused by the human T celledgments on page 1973.
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ty for Blood and Marrow Transplantation.lymphotropic/leukemia virus type-1, has an extremely poor
prognosis [1]. Intensive chemotherapy and autologous stem
cell transplantation have not been shown to improve this
prognosis [2,3]. As a curative treatment, allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) can confer long-
term remission via a graft-versus-ATLL effect in a proportion
of patients with ATLL [4-7]. Recent reports have demon-
strated that allo-HSCT using bonemarrow (BM) or peripheral
blood stem cells (PBSC) from a related or unrelated donor can
effectively treat ATLL, yielding a 3-year overall survival rate
Table 1
Patient Characteristics at Cord Blood Transplantation
Variables No. of Patients
(n ¼ 175)
Age at transplantation, median (range), yr 55 (27-79)
Gender
Male 105
Female 70
Disease status at transplantation
CR 50
Not in CR 116
Unknown 9
Conditioning regimen
FIC 63
RIC 108
Unknown 4
GVHD prophylaxis
Cyclosporine-based 90
Tacrolimus-based 77
Unknown 8
Time from diagnosis to transplantation, d
<200 94
200 75
Unknown 6
Year of transplantation
<2005 71
2005 104
HLA matching*
0 mismatched loci 5
1 mismatched locus 36
2 mismatched loci 73
3 mismatched loci 42
Unknown 19
ABO matching
Matched 56
Minor mismatched 49
Major mismatched 69
Unknown 1
Nucleated cells infused per 107/kg, median
(range)
2.58 (.36-5.34)
CD34-positive cells infused per 105/kg, median
(range)
.85 (.07-5.39)
* Number of mismatches was counted among HLA-A, -B (low-resolution
typing), and DRB1 (high-resolution typing).
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ATLL typically lack a suitable HLA-identical sibling donor
because both the recipients and donors are typically elderly
and because the aggressive ATLL tumor burden reduces the
available time to ﬁnd a suitable unrelated donor within the
Japan Marrow Donor Program. Umbilical cord blood, which
can serve as an alternative to BM or PBSC as a source of stem
cells, has been used primarily to treat children; however, the
number of unrelated-donor cord blood transplantation (CBT)
procedures used to treat adult patients with ATLL is
increasing in Japan. The rapid availability of CBT may provide
a great advantage for patients who require urgent allo-HSCT
to treat aggressive ATLL [17].
Currently, the outcome of CBT in patients with acute
leukemia is comparable to that of other graft sources [18,19];
however, there are few reports on the outcomes of CBT in
patients with ATL [20,21]. Moreover, it is difﬁcult to draw
ﬁrm conclusions regarding the efﬁcacy of this procedure
because of the small number of cases. Therefore, to evaluate
the role of CBT for ATLL in a larger and more recent cohort,
we performed a nationwide retrospective study of patients
with ATLL who underwent CBT as the initial allo-HSCT.
PATIENTS AND METHODS
Data Collection
We analyzed nationwide survey data from the Japan Society for He-
matopoietic Cell Transplantation regarding patients with ATLL who had
undergone an initial CBT betweenMarch2001 andDecember 2009 (n¼ 175).
This analysis included the patients’ clinical characteristics, such as the age at
transplantation, gender, disease status at transplantation, date of trans-
plantation, time from diagnosis to transplantation, conditioning regimens,
and number of infused cells. The number of mismatches was counted with
respect to HLA-A, HLA-B (low-resolution typing), and DRB1 (high-resolution
typing). The present study was approved by the data management com-
mittees of the Japan Society for Hematopoietic Cell Transplantation aswell as
the institutional ethics committee of the Kyushu University Graduate School
of Medical Sciences.
Deﬁnitions
OS was deﬁned as the time from transplantation until death, and pa-
tients who remained alive at the time of the last follow-up were censored.
The causes of deathwere reviewed and categorized as either ATLL-related or
transplantation-related mortality (TRM). ATLL-related mortality was deﬁned
as death caused by a relapse or progression of ATLL, whereas TRM was
deﬁned as any death related to transplantation other than ATLL-related
mortality, according to the judgment of each institution. The patients
were divided into 2 groups according to the conditioning regimen: full-
intensity conditioning (FIC) and reduced-intensity conditioning (RIC). FIC
and RIC were deﬁned according to the proposals of Giralt et al. [22] and
Bacigalupo et al. [23], respectively, with slight modiﬁcations. In the present
study, conditioning regimens that included 5 Gy of total body irradiation
(TBI) in a single fraction or 8 Gy of TBI in multiple fractions, oral busulfan
(BU) at >8 mg/kg, intravenous BU at >6.4 mg/kg, or melphalan (Mel) at
>140 mg/m2 were considered FIC; all others were classiﬁed as RIC.
Statistical Analysis
Descriptive statistics were used to summarize the variables related to
patient demographics and transplantation characteristics. The probability of
the OS time was estimated according to the Kaplan-Meier method. To
evaluate the inﬂuences of confounding factors on acute graft-versus-host
disease (GVHD) and survival, the log-rank test and proportional hazards
modeling were used for the univariate and multivariate analyses, respec-
tively. The Cox proportional hazard model was used for the multivariate
analyses of OS in which all independent variables were incorporated in the
model, followed by the use of a stepwise selection method [24]. Fine and
Gray proportional hazard modeling was used to estimate the effects of the
same variables used in the multivariate analysis for OS on the cumulative
incidence rates of TRM and ATLL-related mortality [25,26]. In these
regression models, the occurrence of GVHD was treated as a time-
dependent covariate [27]. In the analysis of acute GVHD, patients were
assigned to the “no acute GVHD group” at the time of transplantation and
transferred to the “acute GVHD group” at the onset of themaximum grade of
acute GVHD. The landmarkmethodwas used to evaluate the effects of GVHDon OS and the cumulative incidence of disease-associated and treatment-
related deaths among patients who remained alive at 60 days for acute
GVHD and at 100 days for chronic GVHD after transplantation. Factors
associated with at least borderline signiﬁcance (P  .10) in the univariate
analysis were subjected to amultivariate analysis using a backward stepwise
covariate selection. All P values were 2-tailed, and P values .05 were
considered statistically signiﬁcant. All statistical analyses were performed
using EZR (Saitama Medical Center, Jichi Medical University), a graphical
user interface for R (The R Foundation for Statistical Computing, version
2.13.0) [28].RESULTS
Patient Characteristics
The characteristics of 175 ATLL patients who received a
single CBT are shown in Table 1. The median age at CBT was
55 years (range, 27 to 79 years). The cohort comprised 70
women and 105menwith the following ATLL statuses at CBT:
complete remission (CR; n ¼ 50), not in CR (n ¼ 116), and
unknown (n ¼ 9). The conditioning regimen intensity was
classiﬁed as FIC in 63 (36%) patients and RIC in 128 (62%)
patients. FIC was further subdivided into 2 groups as follows:
TBI (n¼47) or non-TBI (n¼15). RICwas also subdivided into 3
groups as follows: ﬂudarabine (Flu) þMel (n ¼ 75), Flu þ BU
(n ¼ 15), and other types (n ¼ 15). Cyclosporine and tacroli-
mus were administered for prophylaxis to 90 (51%) and 77
patients (44%), respectively. Cyclosporine-based prophylaxis
was subdivided into 3 groups as follows: (1) cyclosporine
K. Kato et al. / Biol Blood Marrow Transplant 20 (2014) 1968e19741970alone (n ¼ 33), (2) cyclosporine þ short-term methotrexate
(MTX) (n ¼ 45), and (3) cyclosporine þ mycophenolate
mofetil (MMF; n ¼ 12). Tacrolimus-based prophylaxis was
subdivided into 4 groups as follows: (1) tacrolimus alone
(n ¼ 37), (2) tacrolimus þ short-term MTX (n ¼ 32), (3)
tacrolimusþMMF (n¼ 5), (4) and tacrolimusþ prednisolone
(n ¼ 3). Ninety-four patients (54%) received CBT < 200 days
after diagnosis. One hundred twenty-four (71%) patients
underwent CBTwith 2 HLA-mismatched loci. The numbers of
infused nucleated and CD34-positive cells were 2.58 107/kg
(range, .36 to 5.34  107/kg) and .85  105/kg (range, .07 to
5.39  105/kg), respectively. Engraftment evaluation was
possible in 125 patients (71%) within a median interval of
19 days after CBT (range, 7 to 46 days). Among the survivors,
the median follow-up duration was 22.5 months (range, 0 to
74.5 months).Prognostic Factors for Survival
The OS rates of 175 patients with ATLL who received CBT
were 30.2% (95% conﬁdence interval [CI], 23.0% to 37.4%) at
1 year and 20.6% (95% CI, 13.8% to 27.4%) at 2 years
(Figure 1A). The cumulative incidence rates of ATLL-related
mortality and TRM at 2 years were 31.9% (95% CI, 24.8% to
39.3%) and 46.4% (95% CI, 38.5% to 54.0%), respectively
(Figure 1B). The following confounding factors affectedFigure 1. Survival, adult T cell leukemia/lymphoma (ATLL)-related mortality rates, and
transplantation (CBT). (A) Kaplan-Meier curves of the estimated overall survival ra
peripheral blood stem cells; BM, bone marrow, GVHD, graft-versus-host disease. (B
treated with CBT. (C) Landmark plots of OS to determine the effects of acute GVHD.survival: age, gender, disease status at transplantation, days
from diagnosis to transplantation, date of transplantation,
age at transplantation, conditioning regimen, number of
infused nucleated and CD34-positive cells, ABO compati-
bility, HLA compatibility, GVHD prophylaxis, and the devel-
opment of acute GVHD. A univariate analysis revealed that
higher OS (P < .05) correlated with CR at transplantation,
minor ABO incompatibility, the addition of other agents to
calcineurin inhibitors (MTX or MMF), and the development
of acute GVHD (Table 2). A multivariate analysis was per-
formed to further examine the effects of an age <55 years,
the development of acute GVHD as a time-dependent co-
variate coincident with CR at transplantation, minor ABO
incompatibility, and the addition of other agents to calci-
neurin inhibitors (Table 3). Compared with the absence of
GVHD, the development of acute GVHD was associated
independently with higher OS (hazard ratio [HR], .10; 95% CI,
.01 to 0.94; P ¼ .044).Effects of Acute GVHD on Survival
To further validate the effect of acute GVHD on OS, we
examined survival according to the acute GVHD grade in a
landmark analysis. The median time to onset of acute GVHD
of any grade after transplantation was 21 days (range, 5 to
100 days). Acute GVHD occurred in 80 patients (46%) astransplantation-related mortality (TRM) rates of patients receiving cord blood
tes (OS) of ATLL patients treated with CBT. UCB, umbilical cord blood; PBSC,
) Cumulative incidence curves of ATLL-related mortality and TRM in patients
(D) Landmark plots of OS to determine the effects of chronic GVHD.
Table 2
Univariate Analysis of Risk Factors for Overall Survival
Variables No. OS
Two-Year OS (%) 95% CI P Value
Age 1 <60 yr 134 23.0 15.0-31.0 .080
60 yr 41 12.0 6.0-22.4
Age 2 <55 yr 85 25.4 15.0-35.8 .100
55 yr 90 15.6 7.0-24.2
Sex Female 70 22.3 11.5-33.1 .453
Male 105 19.4 10.8-28.0
Disease status at transplantation CR 50 40.3 25.5-55.1 .003
Not in CR 116 14.3 7.1-21.7
Time from diagnosis to transplantation <200 d 94 22.4 12.8-32.0 .752
200 d 75 19.9 9.7-30.1
Yr of transplantation <2005 71 17.6 8.2-27.0 .160
2005 104 23.1 13.5-31.5
Conditioning regimen FIC 63 20.2 9.8-30.6 .740
RIC 108 20.2 11.8-28.6
Infused nucleated cell dose ( 107/kg) <2 19 10.8 0-29.3 .290
2 145 22.6 14.9-30.3
Infused CD34 cell dose ( 105/kg) <1 97 23.3 13.9-32.7 .396
1 66 19.1 8.0-30.2
ABO matching Matched 56 12.8 3.4-22.2 .024
Minor mismatched 49 30.5 15.5-45.5
Major mismatched 69 20.5 9.9-31.1
HLA matching 0 mismatched 5 30.0 0-77.4 .525
1 mismatched 36 21.6 5.6-37.6
2 mismatched 73 24.6 14.3-35.9
3 mismatched 42 18.1 3.9-32.3
GVHD prophylaxis 1 Cyclosporine-based 90 21.9 12.5-31.4 .710
Tacrolimus-based 77 20.3 10.0-30.4
GVHD prophylaxis 2 (cyclosporine/tacrolimus þ other drug) No 70 12.4 4.8-20.0 .003
Yes 97 32.7 21.1-44.3
Acute GVHD No 59 16.8 5.7-27.9 <.0001
Yes 80 29.4 18.2-40.6
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grade 3, n ¼ 14 patients; and grade 4, n ¼ 6 patients. There
was no signiﬁcant difference in OS between patients with
grades 1 and 2 GVHD (P ¼ 1.00), in contrast to the difference
between patients with grades 1 and 3 GVHD (P ¼ .013).
Moreover, based on the previous national survey analysis of
the effect of acute GVHD on survival in patients with ATLL
[5,15], the effect of acute GVHD on OS in the present study
was evaluated using landmark plots (landmark day 60) ac-
cording to the following 3 categories: (1) no acute GVHD
(n ¼ 38), (2) grade 1 to 2 acute GVHD (n ¼ 53), and (3) gradeTable 3
Multivariate Analysis of Risk Factors for OS
Variables OS
HR 95% CI P Value
Age, yr
<55 1
55 1.15 .63-2.09 .652
Disease status at transplantation
CR 1
Not in CR 1.38 .73-2.63 .190
ABO matching
Matched 1
Minor mismatched .56 .25-1.24 .152
Major mismatched .77 .39-1.48 .337
GVHD prophylaxis (cyclosporine/
tacrolimus þ other drug)
No 1
Yes .76 .42-1.38 .365
Acute GVHD (time-dependent covariate)
No 1
Yes .10 .01-.94 .0443 to 4 acute GVHD (n ¼ 14). The 2-year OS rates for patients
according to the acute GVHD grade were as follows: 24.2%
(95% CI, 11.2% to 39.8%) without acute GVHD; 42.7% (95% CI,
28.1% to 56.6%) with grade 1 to 2 GVHD; and 0% with grade 3
to 4 GVHD (Figure 1C). These analyses demonstrated that the
development of grade 1 to 2 acute GVHDwas associated with
higher OS compared with the absence of acute GVHD
(P ¼ .048), whereas the development of grade 3 to 4 acute
GVHD was associated with lower OS compared with that in
patients with grade 1 to 2 acute GVHD (P ¼ .0003). The cu-
mulative 2-year ATLL-relatedmortality rates according to the
GVHD grades were as follows: 32.6% (95% CI, 19.7% to 46.1%)
for grade 1 to 2 acute GVHD; 29.8% (95% CI, 8.2% to 55.6%) for
grade 3 to 4 acute GVHD; and 45.9% (95% CI, 29.0% to 61.3%)
for no acute GVHD. There was a trend toward a lower risk of
relapse or progression in those who developed grade 1 to 2
acute GVHD relative to those without GVHD. Among patients
with non-CR at transplantation, there was also a trend to-
ward higher 2-year OS (36.7%; 95% CI, 18.7% to 54.9%) in
those who developed grade 1 to 2 acute GVHD than in those
without GVHD (15.6%; 95% CI, 3.4% to 35.9%). These data
suggested a graft-versus-ATLL effect induced by CBT.
Effects of Chronic GVHD on Survival
Chronic GVHD was evaluated in 74 patients who survived
for at least 100 days after transplantation. Chronic GVHD
occurred in 28 patients (37%) with a median time to onset of
115 days (range, 73 to 1287 days) after CBT. The effect of
chronic GVHD on OS was evaluated using landmark plots
(landmark day 100), and the 2-year OS results were as fol-
lows: no chronic GVHD (n ¼ 46), 35.6% (95% CI, 21.0% to
50.0%); limited chronic GVHD (n ¼ 15), 68.1% (95% CI, 35.4%
K. Kato et al. / Biol Blood Marrow Transplant 20 (2014) 1968e19741972to 86.8%); and extensive chronic GVHD (n ¼ 13), 40.4% (95%
CI, 13.4% to 66.4%) (Figure 1D). There was a trend toward a
higher OS among patients with limited chronic GVHD, but
there were no signiﬁcant differences relative to patients
without chronic GVHD (P ¼ .10) and those with extensive
chronic GVHD (P ¼ .12).
Cause of Death
At the last follow-up, 46 patients remained alive and 129
were deceased. The median follow-up time among the sur-
vivors was 22.5 months (range, 0 to 74.5 months). Disease
progression (n ¼ 52) was the leading cause of death. Infec-
tion was the cause of death in 40 patients (31%; bacterial,
n¼ 27 patients; fungal, n¼ 3; viral, n¼ 8; and others, n¼ 2).
Viral infection-related deaths were caused by the following
pathogens: cytomegalovirus, n ¼ 3; adenovirus, n ¼ 2; hu-
man herpesvirus-6, n ¼ 2; and varicella-zoster virus, n ¼ 1.
Among the 27 patients who succumbed to bacterial infec-
tion, 16 died before engraftment at a median of 17 days after
CBT (range, 7 to 38 days). Among the 20 patients who
developed severe acute grade 3 to 4 GVHD, 2 remain alive
without disease progression. However, 9 of the 20 patients
died of GVHD, 5 of disease progression, and 4 of infection.
The Fine and Gray proportional hazards model was
applied to identify the variables affecting ATLL-related mor-
tality and TRM. The pretransplantation variables included
age, gender, disease status at CBT, days from diagnosis
to transplantation, age at transplantation, conditioning
regimen, number of infused nucleated cells, ABO compati-
bility, HLA compatibility, and GVHD prophylaxis. The
following pretransplantation factors associated with a higher
risk of ATLL-related mortality were identiﬁed in a multivar-
iate analysis: not in CR at CBT (HR, 3.37; 95% CI, 1.12 to 10.2;
P ¼ .032) and an age > 55 years at CBT (HR, 2.32; 95% CI, .98
to 5.48; P ¼ .054). The following pretransplantation factors
were associated with a marginally higher risk of TRM: lower
number of infused nucleated cells (2  107/kg versus
<2  107/kg; HR, .56; 95% CI, .30 to 1.02; P ¼ .059) and GVHD
prophylaxis with a calcineurin inhibitor alone (additional
agents plus calcineurin inhibitors versus calcineurin in-
hibitors alone; HR, .60; 95% CI, .34 to 1.07; P ¼ .064).
DISCUSSION
We present here the results of the largest retrospective
study of ATLL patients receiving CBT; these results have
extended our knowledge relative to that gained from other
studies, which were limited by the numbers of cases
[15,20,21]. Because graft source selection is strongly inﬂu-
enced by the donor availability, it is difﬁcult to directly
compare the outcomes of CBT with those of other allo-HSCT
modalities. Nevertheless, the outcome of CBT for ATLL in the
previous nationwide survey, with a 3-year OS rate of 17%,
was clearly unsatisfactory because the study period corre-
sponded with the developmental phase of CBT in adult pa-
tients [15]. Recent improvements in the outcome of CBT have
been expected after optimization of the number of cells used
for CBT and the improved HLA-compatibility of cord blood
units [29-31]. Consequently, a recent nationwide survey data
of adults with acute non-ATLL leukemia revealed no differ-
ences in the outcome of CBT in comparison with those of
other allo-HSCT modalities [18,19]. However, the updated
data (through December 2009) indicated that CBT for ATLL
remained associated with a poorer 3-year OS of 20.6%,
compared with OS of 34.4% among the 374 patients who
received related BM or PBSC and 37.1% among the 319patients who received unrelated BM (P < .0001) (Figure 1A).
Therefore, the aim of the present study focused on the
feasibility of CBT in the context of a larger cohort of patients
with ATLL.
In the present study, 2 important ﬁndings were identiﬁed
regarding CBT for ATLL. First, CBT cured patients with ATLL
partly through a graft-versus-ATLL effect. Second, the high
rate of TRM (approximately 50%) remains a signiﬁcant
problem. The OS curve for ATLL patients who received CBT
reached a plateau by 3 years, suggesting long-term survival
of selected patients, although the outcome of CBT for ATLL
(3-year OS, 20%) did not compare favorably with those of
other allo-HSCT modalities. Regarding the prognostic factors
affecting survival, our present univariate analysis identiﬁed
the 5 following signiﬁcant variables associated with higher
OS: (1) age, (2) disease status at transplantation, (3) ABO
compatibility, (4) addition of agents such as MTX or MMF to
calcineurin inhibitors for GVHD prophylaxis, and (5) devel-
opment of acute GVHD. Further, the multivariate analysis
revealed that the development of acute GVHD was inde-
pendently associated with better OS relative to the absence
of acute GVHD. A landmark analysis showed that the devel-
opment of grade 1 to 2, or so called mild-to-moderate acute
GVHD, was associated with better OS when compared with
the absence of acute GVHD. There was also a trend toward a
lower risk of relapse or progressionwith the development of
acute GVHD when compared with the absence of GVHD and
better OS in patients with limited chronic GVHD. Taken
together, these data suggest the presence of a curative graft-
versus-ATLL effect conferred by CBT.
However, it is typically difﬁcult for physicians to optimize
the effects of acute GVHD to prevent disease progression via
graft-versus-ATLL. Therefore, a more realistic attempt would
be the control of pretransplantation factors that might affect
the CBT outcome and, thus, enhance the beneﬁt of allo-HSCT.
The multivariate analysis performed herein with respect to
ATLL-related deaths identiﬁed disease status at CBT as the
most important factor. ATLL usually resists conventional
chemotherapy and must be treated soon after diagnosis
because of the rapid proliferation of tumor cells, which
generates a high tumor burden [2,3]. In the future, novel
agents, such as mogamulizumab, a humanized anti-CCR4
monoclonal antibody, might improve CBT-associated sur-
vival by decreasing the tumor burden before transplantation
[32-35]. Another possibility for improving survival might be
reducing the time from diagnosis to transplantation while
patients with ATLL remain chemosensitive. Moreover, CBT
provides a considerable advantage for patients who require
urgent allo-HSCT to combat aggressive ATLL.
In the present study, we have shown that CBT is feasible
and curative. However, the high rate of TRM remained a
signiﬁcant problem. Bacterial infection caused the highest
incidence of death (21%) during the neutropenic period. The
infusion of lower numbers of nucleated cells (<2  107/kg),
which is usually associated with delayed engraftment, was
marginally associated with TRM. Neutrophil recovery is
slower in patients treated via CBT, and immunosuppressed
patients with ATLL might be at an increased risk of devel-
oping more frequent opportunistic infections [36]. Improved
supportive care to prevent bacterial infection is required af-
ter CBT for patients experiencing a prolonged neutropenic
period. The ongoing development of better graft engineering
[37] or double-CBT [38] might facilitate rapid neutrophil
recovery and, thus, help to reduce the TRM rate in CB
recipients.
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concerning the effect of chronic GVHD on survival should be
interpreted with caution because the relatively small num-
ber of patients who developed chronic GVHD did not allow
us to evaluate the effect of this condition on survival in a
multivariate analysis. Instead, wewere limited to performing
a landmark analysis of OS according to the severity of chronic
GVHD. Certainly, we detected a trend toward higher OS in
patients with limited chronic GVHD when compared with
patients without chronic GVHD, suggesting the possible
presence of a graft-versus-ATLL effect. However, these results
might be biased because of insufﬁcient statistical power. Our
future studies will assess the effect of chronic GVHD on the
outcome of CBT for the treatment of ATLL after a long-term
follow-up. Although the present study employed, to our
knowledge, the largest cohort of CBT-treated patients to date
and our results demonstrated that CBT is a feasible and
effective treatment, this was a retrospective analysis.
Therefore, this ﬁnding requires conﬁrmation in prospective
studies. To establish reliable criteria for CBT administration, a
prospective multicenter clinical trial is underway in Japan to
evaluate the safety and efﬁcacy of CBT combined with Flu,
Mel, and low-dose TBI (4 Gy) along with GVHD prophylaxis
(tacrolimus and MMF [39]).
In conclusion, CBT is feasible and effective for patients
with ATLL and acts via a graft-versus-ATLL effect. However,
the outcome of CBT is unsatisfactory when compared with
those of other allo-HSCT modalities. The high rate of TRM
must be reduced, and the development of novel strategies is
required to further improve the outcome of CBT.
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